Clinical Scorecard: Evaluating Cost Efficiency and Safety of Dose Rounding for Trastuzumab Deruxtecan in Chinese Patients: Insights from a Real-World Study
At a Glance
Category
Detail
Condition
HER2-positive cancers
Key Mechanisms
Dose rounding strategies to minimize drug waste and reduce costs
Target Population
Chinese patients with breast cancer, non-small cell lung cancer, or gastric cancer
Care Setting
Cancer hospital
Key Highlights
Dose rounding down saved CNY 897,840 in costs.
Dose rounding up avoided 4,368.3 mg of drug waste.
Dose deviations ranged from 0.10% to 9.97%, within the 10% acceptable limit.
Adverse events were comparable across dose rounding groups.
The study supports cautious implementation of dose rounding in clinical practice.
Guideline-Based Recommendations
Diagnosis
Confirmed diagnosis of breast cancer, NSCLC, or gastric cancer required.
Management
Trastuzumab deruxtecan administered at 6.4 mg/kg for gastric cancer or 5.4 mg/kg for breast cancer/NSCLC every 3 weeks.
Monitoring & Follow-up
Laboratory tests including complete blood count, liver function, and renal function before and after treatment.
Risks
Common adverse reactions include nausea, vomiting, fatigue, leukopenia, neutropenia, thrombocytopenia, and musculoskeletal pain.
Patient & Prescribing Data
141 patients receiving trastuzumab deruxtecan between 2024 and 2025.
Dose rounding strategies can reduce costs and waste without compromising safety.
Clinical Best Practices
Implement dose rounding within a 10% deviation range.
Monitor adverse events consistently across treatment groups.
Utilize comprehensive medical records for patient data accuracy.
Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody
